

Eylea® (aflibercept) Injection



When requesting Eylea® (aflibercept), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial uses and meet the specific coverage guidelines for the covered indications.

FDA-approved indications

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR) in patients with DME

Approved Off-label Compendial uses

- Macular Choroidal Neovascularization

Coverage Guidelines

For all approved indications the individual meets **both** of the following criteria for approval:

- A. Does not have ocular or periocular infection
- B. Does not have active intraocular inflammation

Approval duration: 12 months

Dosing Recommendations

- **Neovascular (Wet) Age-Related Macular Degeneration** -2mg by intravitreal injection every 4 weeks for the first 3 months, followed by 2mg via intravitreal injection once every 8 weeks.
- **Macular Edema Following Retinal Vein Occlusion-** 2mg by intravitreal injection once every 4 weeks
- **Diabetic Macular Edema and Diabetic Retinopathy (DR) in Patients with Diabetic Macular Edema-**2mg administered via intravitreal injection every 4 weeks for the first 5 doses followed by 2mg every 4 or 8 weeks.

References

1. Eylea® prescribing information. Tarrytown, NY: Regeneron Pharmaceuticals Inc.: May 2017.
2. Aflibercept (Eylea®). In: DRUGDEX® System. Micromedex 2.0. Greenwood Village, CO; Thompson Reuters (Healthcare). [Accessed April 17, 2018].

3. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. *Ophthalmology*. 2014; 121(1):188.
4. Schmidt-Erfurth U et al. Guideline for the Management of Diabetic Macular by the European Society of Retina Specialists (EURETINA). *Ophthalmologica* 2017; 237:185-222.
5. Rosenbaum JT (2017). Uveitis: Treatment. J Trobe (Ed.). Up-to-date. Retrieved April 18.2018.
6. American Academy of Ophthalmology (2017). Preferred Practice patter. Diabetic Retinopathy.
7. American Academy of Ophthalmology (2015). Preferred Practice Pattern. Age-Related Macular Degeneration.
8. American Academy of Ophthalmology (2017) Retina Summary Benchmarks for Preferred Practice Pattern Guidelines.